Targeting the Lactate‐Lactylation Axis in Cancer Immunotherapy Resistance: From Tumor Acidosis to Context‐Dependent Immune Reprogramming
Medicinal Research Reviews · 16.11.2026
DOI: 10.1002/med.70127 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 16.11.2026. Verfasst von Xuejiao Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Fir…. Die Arbeit nennt 164 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Construction Fund of Key Medical Disciplines of Hangzhou.
Abstract (Originalsprache)
Lactate is now recognized as an active immunometabolic regulator in the tumor microenvironment (TME), not simply as a glycolytic byproduct. Its immunological effects arise through several related but distinct routes. Extracellular acidosis, glucose competition, and impaired monocarboxylate transporter‐dependent flux can impair CD8 + T cells, natural killer cells, and dendritic cells. Lactate‐ and proton‐sensing receptors can also favor suppressive myeloid and regulatory‐cell programs. Histone and non‐histone lactylation add another layer by linking lactate availability to chromatin regulation and protein function. During sustained or repeated metabolic stress, these processes may support regulatory T‐cell fitness, suppressive programs in tumor‐associated macrophages and myeloid‐derived suppressor cells, checkpoint expression, and resistance to immunotherapy. Lactylation is a plausible mediator through which sustained metabolic stress may be converted into persistent immune reprogramming; however, post‐withdrawal persistence and cellular memory remain to be demonstrated in cancer. We distinguish lactate‐dependent regulation from acidosis and evaluate the links to immune dysfunction and treatment resistance by their temporal, causal, and clinical support. This framework defines tests of post‐exposure persistence and connects mechanistic evidence and pharmacological specificity to biomarker development and mechanism‐matched trial design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzho…
- Department of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
- Zhejiang Moganshan Institute of Geomagnetism Large-scale Scientific Facility, Huzhou, zhejiang, China.
- Westlake Laboratory of Life Sciences and Biomedicine of Zhejiang Province, Westlake University, Hangzhou, zhejiang, China.
ORCID-Profile: Mengmeng Lin, Chong Zhang, Nengming Lin, Yangling Li
Förderung
- National Natural Science Foundation of China
- The Construction Fund of Key Medical Disciplines of Hangzhou
Zitieren
APA
Liang, X., Lin, M., Zhang, C., Yang, Q., Lin, N., & Li, Y. (2026). Targeting the Lactate‐Lactylation Axis in Cancer Immunotherapy Resistance: From Tumor Acidosis to Context‐Dependent Immune Reprogramming. Medicinal Research Reviews. https://doi.org/10.1002/med.70127
Vancouver
Liang X, Lin M, Zhang C, Yang Q, Lin N, Li Y. Targeting the Lactate‐Lactylation Axis in Cancer Immunotherapy Resistance: From Tumor Acidosis to Context‐Dependent Immune Reprogramming. Medicinal Research Reviews. 2026. doi:10.1002/med.70127
BibTeX
@article{Liang2026,
author = {Liang, Xuejiao and Lin, Mengmeng and Zhang, Chong and Yang, Quanyao and Lin, Nengming and Li, Yangling},
title = {Targeting the Lactate‐Lactylation Axis in Cancer Immunotherapy Resistance: From Tumor Acidosis to Context‐Dependent Immune Reprogramming},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70127}
}
EUVIMED